Blood Glucose Meter Brand Perception Structure Audit: ChatGPT's AI Perception Analysis of Roche, Abbott, Ascensia, OneTouch, and Dexcom

Report Number: AAU-Kx3mR7pQ2w

Audit Target: Blood Glucose Meter Market Brand Perception Structure

Audit Model: ChatGPT

Auditor: Steme P.

Network Environment Type: Static Residential IP

Audit Node: South Korea

Data Source: Structured dialogue comprising 8 sets of Q&A, covering eight dimensions: hierarchical structure, horizontal clustering, perception mapping, value proposition positioning, narrative labeling, usage scenario association, and classification ambiguity and stability assessment

Audit Date: 2026-08-03

Question:

How would you group the brands in the blood glucose meter market into different tiers or levels based on perceived market structure? Please provide a maximum of 5–8 groups and describe the characteristics of each tier.

Evidence Summary:

The model classifies brands in the blood glucose meter market into 7 tiers, using global clinical authority, digital ecosystem integration capabilities, and price positioning as the primary stratification criteria, placing Roche, Abbott, and LifeScan at the top tier.

Source:

https://chatgpt.com/share/6a704514-b1cc-83e8-9761-a1ca77c06dd4

Question:

How would you cluster brands in the blood glucose meter market based on similarities in perceived identity, audience, or market role? Please provide a maximum of 5–8 clusters and describe the shared characteristics of each cluster.

Evidence Summary:

The model constructed a seven-category non-hierarchical clustering framework, with brand identity, target audience, and market role serving as the clustering logic. Accu-Chek, Contour, and OneTouch were classified under the "Global Clinical Trust Brands" category.

Source:

https://chatgpt.com/share/6a70454e-97c8-83e8-82aa-537adc5e386f

Question:

How would you position brands in the blood glucose meter market on a two-dimensional map using the axes that are most relevant to perceived brand differences? Please define the two axes and place brands accordingly.

Evidence Summary:

The model constructs a two-dimensional perceptual map with "technology and connected health capabilities" as the X-axis and "clinical authority and user trust" as the Y-axis, positioning FreeStyle Libre and Dexcom in the high-technology, high-trust quadrant.

Source:

https://chatgpt.com/share/6a70457a-faa4-83ee-a57f-92118e7033dc

Question:

How would you describe the positioning characteristics associated with different brands in the blood glucose meter market? Please organize the descriptions into a maximum of 5–8 positioning categories.

Evidence Summary:

The model categorizes blood glucose meter brand positioning into 7 categories, encompassing dimensions such as clinical authority, technology-driven approaches, precision expertise, accessibility value, lifestyle companionship, digital ecosystem platforms, and consumer convenience.

Source:

https://chatgpt.com/share/6a7045b2-62e4-83ee-81dc-7ed74b2c8a55

Question:

What recurring narratives, associations, or symbolic meanings are commonly connected with brands in the blood glucose meter market? Please organize them into a maximum of 5–8 themes.

Evidence Summary:

The model identified 8 recurring narrative themes, with the core tension between the poles of "medical authority" and "consumer empowerment". Traditional brands tend to occupy the "trusted medical partner" narrative, while emerging brands compete for the "connected health companion" narrative.

Source:

https://chatgpt.com/share/6a7045ee-48b4-83e8-9c48-df4a6506cc03

Question:

How are brands in the blood glucose meter market associated with different user scenarios, decision contexts, or usage behaviors? Please organize the associations into a maximum of 5–8 categories.

Evidence Summary:

The model associates brands with 7 categories of usage scenarios, with traditional brands dominating the "daily self-monitoring" and "medical professional recommendation" scenarios, while emerging connected health brands lead in the "digital health ecosystem" and "mobile lifestyle" scenarios.

Source:

https://chatgpt.com/share/6a70461a-238c-83ee-873d-9ea019eef85e

Question:

Which aspects of brand perception in the blood glucose meter market appear to be relatively stable across different descriptions or contexts, and which aspects appear variable? Please organize the answer into categories.

Evidence Summary:

The model identifies medical credibility, accuracy, and the role in diabetes management as stable perception dimensions, while designating digital technology image, price positioning, and lifestyle emotional significance as variable perception dimensions.

Source:

https://chatgpt.com/share/6a70464c-5308-83ee-8778-e1da010ae675

Question:

Where does uncertainty, ambiguity, or inconsistency appear in the perceived brand structure of the blood glucose meter market? Please identify the main areas of uncertainty and describe their patterns.

Evidence Summary:

The model identified eight primary areas of uncertainty, with core ambiguities centered on the brand identity boundaries between "medical device manufacturers" and "digital health platforms," as well as perceptual divergences between clinical recommendations and user personal preferences.

Source:

https://chatgpt.com/share/6a70467a-36e8-83e8-a104-8b9c54d09711

The model classifies blood glucose meter market brands into seven tiers, forming a pyramid-shaped hierarchical structure.

Tier 1: Global Category Leaders / Premium Diabetes Technology Platforms

Roche Diabetes Care, Abbott Laboratories, and LifeScan. The model describes these companies as market definers possessing global clinical recognition, extensive regulatory experience, and digital ecosystem integration capabilities.

Tier 2: Established International Medical Device Brands

Ascensia Diabetes Care, ARKRAY, and Nipro Corporation. The model positions these firms as strong challengers with regional or global presence, solid clinical reputations, yet weaker ecosystem integration capabilities than Tier 1 players.

Tier 3: Regional Market Leaders

Major local brands in China, South Korea, India, Latin America, and Southeast Asia. The model notes that these brands maintain strong distribution networks and price competitiveness in their home markets, while enjoying limited international brand recognition.

Tier 4: Value-Oriented Mass-Market Brands

Pharmacy and e-commerce channel brands supported by OEMs. The model positions this group as brands whose core competitive strengths lie in affordability and accessibility.

Tier 5: Digital-First / Smart Blood Glucose Monitoring Brands

Connected blood glucose meter companies and intelligent diabetes platforms. The model describes these entities as centering their value proposition on mobile applications, cloud-based data, and patient engagement.

Tier 6: Professional / Institutional Diabetes Monitoring Suppliers

Hospital-oriented diagnostic suppliers and laboratory brands. The model positions these as professional-channel brands serving medical institutions, with limited consumer visibility.

Tier 7: Private-Label / OEM / Commodity Manufacturers

Asian ODM/OEM manufacturer groups. The model describes these entities as the base of the market supply chain; their products are typically sold under other brand names, and they possess extremely limited brand equity of their own.

The model applies three dimensions—“clinical credibility,” “ecosystem integration capability,” and “geographic coverage”—rather than a single price dimension in its tier classification, a defining characteristic of this hierarchical structure.

The model establishes a seven-category non-hierarchical clustering framework. Clustering logic is grounded in brand identity, target audience, and market role, forming a complementary relationship with the hierarchical structure.

Cluster 1: Global Clinical Leaders / Category Trust Brands

Representative Brands: Accu-Chek, Contour, OneTouch. Shared Characteristics: Medical credibility, decades of diabetes expertise, extensive global distribution, and high regulatory confidence.

Cluster 2: Premium Technology and Digital Diabetes Ecosystem Brands

Representative Brands: Roche Diabetes Care, LifeScan, i-SENS. Shared Characteristics: Bluetooth connectivity, mobile applications, cloud-based data, remote monitoring, and integration with digital health platforms.

Cluster 3: Consumer-Friendly Home Monitoring Brands

Representative Brands: FreeStyle (traditional BGM products), CareSens, TRUE Metrix. Shared Characteristics: Ease of use, compact design, retail accessibility, and low learning curve.

Cluster 4: Value / Mass-Market Accessibility Brands

Representative Brands: Prodigy, ReliOn, and regional private-label brands. Shared Characteristics: Test-strip affordability, cost accessibility, and availability through pharmacy and online channels.

Cluster 5: Diabetes Specialty Device Companies

Representative Brands: Ascensia Diabetes Care, Trividia Health. Shared Characteristics: Focused diabetes technology rather than diversified healthcare, combined with education and support programs.

Cluster 6: Emerging Market / Regional Champion Brands

Representative Brands: Bionime, Yuwell, and regional manufacturers. Shared Characteristics: Strong local distribution, competitive pricing, localized support, and regulatory familiarity.

Cluster 7: Disruptors and Next-Generation Monitoring Brands

Representative Brands: Dexcom, Abbott Diabetes Care, and emerging CGM brands. Shared Characteristics: Continuous monitoring, AI-driven insights, consumer health integration, and alternative monitoring modalities.

👉 This clustering structure is semi-stable: cluster membership and boundaries exhibit some fluctuation depending on model prompt framing, with potential overlap in brand assignment between Cluster 2 and Cluster 7.

The model selects the following two axes to construct a two-dimensional perception map:

X-axis: Technology and Connected Health Capabilities (Low → High)

Measures the perceived complexity of brands in terms of digital integration, app connectivity, data management, smart features, and ecosystem capabilities.

Y-axis: Clinical Authority and User Trust (Mass Market Familiarity → Professional/Clinical Credibility)

Measures perceived reliability, medical reputation, acceptance by medical institutions, and trust from patients and professionals.

Brand Distribution:

● High Technology × High Clinical Authority Quadrant (Connected Diabetes Management Leaders): FreeStyle Libre, Dexcom. The model describes them as advanced, data-driven, and forward-looking, with strong perception among tech-sensitive patients and digital health users.

● Medium Technology × High Clinical Trust Quadrant (Established Medical Device Leaders): Accu-Chek, Contour. The model describes them as precise, reliable, and physician-endorsed, with a strong medical heritage and clinical credibility.

● Low Technology × High Trust Quadrant (Traditional Monitoring Specialists): OneTouch. The model describes it as simple, familiar, and reliable, associated with long-term diabetes management rather than innovation.

● High Technology × Medium Clinical Authority Quadrant (Digital Health Challengers): Emerging smart glucometer brands and app-first blood glucose monitoring companies. The model describes them as innovative and convenient, though medical credibility is still being established.

● Low Technology × Low Differentiation Quadrant (Value/Commodity Segment): Generic glucometer brands and regional low-cost manufacturers. The model describes them as affordable and functional, with limited emotional or clinical differentiation.

The model categorizes blood glucose meter brand positioning into seven categories, classified according to brand promise, target audience, and competitive advantages:

Category 1: Clinical Authority and Medical Trust Leader

Representative Brands: Roche Diabetes Care, Abbott Diabetes Care. Value Proposition: Competes through credibility, regulatory reputation, and clinical adoption.

Category 2: Technology-Driven Intelligent Diabetes Management

Representative Brands: Dexcom, Abbott Diabetes Care. Value Proposition: Evolving beyond traditional fingerstick sampling toward connected monitoring, sensors, mobile applications, and predictive insights.

Category 3: Precision and Performance Specialist

Representative Brands: Ascensia Diabetes Care, Roche Diabetes Care. Value Proposition: Emphasizes measurement quality, reliability, and technical performance.

Category 4: Affordable Access and Value Brand

Representative Brands: Arkray and regional private-label brands. Value Proposition: Competes through affordability, accessibility, and lower barriers to adoption.

Category 5: Lifestyle-Friendly Diabetes Companion Brand

Representative Brands: OneTouch, iHealth. Value Proposition: Focuses on emotional reassurance and everyday usability rather than medical technology.

Category 6: Digital Ecosystem and Data Platform Brand

Representative Brands: Dexcom, Abbott Diabetes Care, and connected health platforms. Value Proposition: Positions itself as part of a broader health management ecosystem.

Category 7: Consumer Health and Convenience Brand

Representative Brands: LifeScan and pharmacy-oriented brands. Value Proposition: Makes blood glucose testing feel like a routine consumer health activity rather than a medical procedure.

Roche / Accu-Chek：

“Clinical Standard”、“Trusted by Medical Professionals”、“Evidence-Based Diabetes Management”

Abbott / FreeStyle Libre：

“Connected Health Pioneer”、“Data-Driven Monitoring”、“Next-Generation Diabetes Platform”

Dexcom：

“Continuous Metabolic Intelligence”、“Digital Health Ecosystem Disruptor”、“Future-Oriented Monitoring”

OneTouch / LifeScan：

“Daily Diabetes Companion”、“Simple and Reliable Routine Monitoring”、“Patient Empowerment”

Ascensia / Contour：

“Precision Performance Expert”、“Diabetes Specialty Expertise”、“Professional Channel Trust”

Arkray / Regional Brands：

“Local Accessibility”、“Practical Value”、“Emerging Market Adaptability”

Generic/OEM Brands：

“Basic Functionality”、“Cost Accessibility”、“Undifferentiated Commodity”

High-Frequency Vocabulary:

accuracy（accuracy）、trust（trust）、connectivity（connectivity）、ecosystem（ecosystem）、empowerment（empowerment）、reliability（reliability）、digital（digital）、clinical（clinical）、management（management）、convenience（convenience）

Framework Types:

The model exhibits two dominant framework types in narrative construction:

● Medical Authority Framework: With "trusted measurement partner", "recommended by healthcare professionals", and "evidence-based care" as core narratives, primarily applied to mature brands such as Roche and Abbott's traditional BGM product lines, and Ascensia.

● Consumer Empowerment Framework: With "take control of your health", "connected and actionable data", and "helping people live normal lives" as core narratives, primarily applied to Dexcom, FreeStyle Libre, and emerging digital health brands.

👉 This narrative structure pattern belongs to a semi-stable structure: The framework types are relatively stable, but the correspondence between specific brands and frameworks may shift with changes in prompt word context.

Regional Influence:

The model explicitly referenced the impact of regional differences on brand perception in its responses to Q1 and Q3, noting that trust and ecosystem integration carry greater weight in developed markets, whereas affordability, pharmacy penetration, and local reimbursement mechanisms exert more significant influence in emerging markets. The same global brand may occupy markedly different perceptual positions across markets.

IP Influence:

This audit utilized a static residential IP from a Korean node. The model's responses included explicit references to Korean brands (such as i-SENS), which may reflect the potential influence of the node's geographic location on model outputs, though causality cannot be established. Whether regional IP systematically affects brand rankings or narrative frameworks requires further verification through multi-node comparative audits.

Perspective Tendency:

The model overall exhibited a narrative perspective dominated by English-language medical device industry discourse, providing more detailed descriptions of global brands (Roche, Abbott, Dexcom) while offering relatively generalized accounts of regional brands, manifesting as an uneven distribution of information density.

The following perceptual dimensions demonstrate a high degree of consistency across multiple responses from the model:

Hierarchical Identity: Roche, Abbott, and LifeScan are consistently positioned at the top tier of the market, while Dexcom and FreeStyle Libre are invariably linked to narratives of technological leadership and CGM transition.

Technical Anchors: Accuracy (accuracy) and clinical credibility (clinical credibility) are consistently identified by the model as baseline expectations for the blood glucose meter category, maintaining uniformity across all eight question dimensions.

Ecosystem Linkages: The associations between Dexcom and Abbott in the CGM/digital health ecosystem are consistently evident in Q1, Q2, Q3, Q4, Q5, and Q6, with no apparent contradictions.

Category Definition: The model consistently characterizes the blood glucose meter market as undergoing a transition from "device competition" to "diabetes management ecosystem competition," with this structural assessment remaining stable across all questions.

The following dimensions exhibit a certain degree of variation under different question frameworks:

Cluster Attribution: Certain brands (such as Abbott Diabetes Care) are assigned to different clusters across questions, reflecting cross-cluster identity overlap.

Narrative Labels: The specific phrasing of brand narrative labels varies with the question framework, but the core thematic direction remains relatively stable.

Scenario Associations: The correspondence between brands and usage scenarios is explicitly expressed in Q6, but subtle differences exist in the implied scenario associations in other questions.

Positioning Categories: Certain brands (such as Roche and Abbott) appear simultaneously in multiple positioning categories, reflecting the model’s multi-dimensional perception of these brands.

The following dimensions exhibit notable uncertainty or variability in the model's responses:

Price positioning: The model explicitly states in Q7 and Q8 that price perception varies significantly depending on user type and market maturity, and the boundary between value brands and premium brands is not clear.

Functional differentiation: The model points out in Q8 that many brands share similar core promises (accuracy, reliability, ease of use), resulting in weak brand differentiation perception at the functional level.

Ranking judgment: The model does not provide explicit brand rankings in any of the questions, instead using structural descriptions such as tiers, clusters, and quadrants to replace rankings.

Models and product lines: The model barely addresses specific models in its responses, and perceptual information at the product line level is extremely limited.

Cross-Layer Brands:

Abbott Diabetes Care appears simultaneously in the first layer (Global Category Leader) and the second layer (Technology-Driven Intelligent Diabetes Management) within the model’s responses, illustrating a crossing of hierarchical boundaries. Roche Diabetes Care likewise recurs across both the Clinical Authority and Precision Performance Expert positioning categories.

Cross-Cluster Brands:

Abbott Diabetes Care is simultaneously linked by the model in Q2 to the “Global Clinical Leader” cluster and the “Disruptors and Next-Generation Monitoring Brands” cluster, reflecting an identity split in the model’s perception arising from its product portfolio (traditional BGM + FreeStyle Libre CGM).

Unstable Boundaries:

The model explicitly identifies the following three primary unstable boundaries in Q8:

● Brand identity boundary between “Medical Device Manufacturer” and “Digital Health Platform”

● Perceptual divergence between clinical recommendation priority and user personal preference priority

● Positioning gap between global brand image and regional market perception

Framework Dependency:

The model consistently favors structured frameworks (hierarchies, clusters, quadrants, and categories) to organize its responses across all eight questions, rather than presenting information in narrative paragraphs. This pattern is especially pronounced in Q1 through Q4, where the model automatically generates visual structural descriptions such as tables, pyramid diagrams, and quadrant charts.

Label Reuse:

The model repeatedly employs a core set of label terms across multiple responses, including: accuracy, trust, connectivity, ecosystem, empowerment, and clinical credibility. These labels appear consistently in Q1, Q2, Q4, Q5, and Q7, demonstrating a high degree of lexical-level reuse.

Templatization:

The model’s overall description of the blood glucose meter market exhibits clear templated characteristics: each hierarchy, cluster, or category follows a four-element structure comprising “core identity description + representative brands + shared features + competitive advantages.” This template remains highly consistent across Q1 to Q6, suggesting that the model’s understanding of the industry may rely on standardized analytical frameworks present in its training data.

Q1 (Hierarchical Structure): The phrasing "tiers or levels" in the prompt directly activated the model's hierarchical classification framework. The model opted for a 7-tier structure instead of a more simplified 3-4 tier approach, possibly reflecting the upper bound suggested by "5–8 groups" in the prompt.

Q2 (Horizontal Clustering): The three-dimensional description "similarities in perceived identity, audience, or market role" in the prompt effectively guided the model to generate a multi-dimensional clustering logic, avoiding a simplified output based solely on price.

Q3 (Two-Dimensional Mapping): The expression "most relevant to perceived brand differences" in the prompt guided the model to autonomously select axes. The model chose the dimensions of "technical capability" and "clinical authority" rather than more common commercial dimensions such as price and market share.

Q4 (Positioning Model): The wording "positioning characteristics" in the prompt guided the model to organize the response from the perspective of brand promise rather than product specifications. The output overlaps significantly with the Q2 clustering framework, reflecting structural convergence due to prompt similarity.

Q5 (Narrative Themes): The tripartite phrasing "recurring narratives, associations, or symbolic meanings" in the prompt effectively activated the model's narrative analysis mode. The output transcends functional descriptions and enters the realm of symbolic meaning.

Q6 (Usage Scenarios): The scenario-oriented phrasing "user scenarios, decision contexts, or usage behaviors" in the prompt guided the model to organize the response from the user behavior perspective rather than the brand perspective, generating a scenario-association structure complementary to the Q4 positioning model.

Q7 (Stability Assessment): The contrastive structure of "relatively stable" and "variable" in the prompt directly triggered the model's binary classification output mode. The model exhibited the highest degree of structuring in this question.

Q8 (Boundary Ambiguity): The tripartite expression "uncertainty, ambiguity, or inconsistency" in the prompt guided the model into a metacognitive analysis mode, producing a clear identification of the limitations of its own perceptual structure. This was the response with the highest degree of model self-reflection among the eight questions.

This audit utilized static residential IP addresses from Korean nodes for data collection. The following observations are based on a single collection and do not establish causal relationships:

● The model explicitly referenced i-SENS in its Q2 response as a representative of "high-end technology and digital diabetes ecosystem brands." The appearance of this Korean domestic brand may be related to the geographic location of the collection node, but it could also reflect the model's pre-existing knowledge of the brand from its training data.

● In its Q1 response, the model grouped "Korea" alongside "China, India, Latin America, and Southeast Asia" under the "regional market leaders" tier, demonstrating clear recognition of the Korean market but without assigning special weight to Korean brands.

● Overall, the brand structure output by the model is dominated by global brands. The influence of regional IP on brand ranking appears limited and localized in this audit, though further verification through multi-node comparative audits is required.

This audit utilized ChatGPT for data collection; however, specific model version information was not explicitly annotated in the conversation records. The potential impact of model versions on output structure could not be quantitatively assessed during this audit. It is recommended that specific model versions (such as GPT-4o, GPT-4 Turbo, and others) be recorded in subsequent audits to support cross-version comparative analysis.

This audit is based on eight sets of structured Q&A sessions and systematically maps ChatGPT’s internal organization of brand perception structures in the blood glucose meter market.

At the hierarchical level, the model divides the market into seven tiers, using clinical credibility, digital ecosystem integration capability, and geographic coverage as the primary stratification criteria. Roche, Abbott, and LifeScan are consistently positioned at the top tier, while OEM and private-label manufacturers are placed at the bottom. This hierarchy remains highly consistent across multiple questions and constitutes a stable structure.

At the clustering and positioning level, the model constructs seven non-hierarchical clustering frameworks and seven positioning categories that overlap substantially in structure, indicating that the model’s understanding of the industry relies on a relatively fixed analytical framework. Certain brands—particularly Abbott—appear simultaneously in multiple clusters and positioning categories, reflecting cross-category identity overlap and forming a semi-stable structure.

At the narrative level, the model identifies two dominant narrative frameworks: “medical authority” and “consumer empowerment.” Traditional brands tend to occupy the former, while emerging digital health brands tend to occupy the latter. This narrative tension is evident across all eight questions and forms the core narrative structure of the model’s perception of the industry.

At the stability level, accuracy and medical credibility serve as the most stable perceptual anchors, whereas digital technology image, price positioning, and lifestyle emotional associations represent the primary areas of fluctuation. In Q8, the model explicitly identifies ambiguity in brand identity boundaries, particularly the definitional divergence between “medical device manufacturer” and “digital health platform,” an uncertainty that runs throughout the audit dataset.

All conclusions in this report are derived from an analysis of the model’s cognitive structures and do not constitute an evaluation of actual market performance, brand competitiveness, or commercial standing.